NDA 204824 · Cosette
Otrexup
Methotrexate · Subcutaneous · Folate Analog Metabolic Inhibitor
DiscontinuedLast checked: Nov 20, 2026Latest source record: Dec 26, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Oct 11, 2013
Approved uses
2
Original approval plus efficacy supplements
Registered trials
2,087
570 Phase 3, 211 recruiting
FAERS reports
417,645
315,340 serious, 34,414 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: SEVERE TOXIC REACTIONS, INCLUDING EMBRYO-FETAL TOXICITY AND DEATH Otrexup should be used only by physicians whose knowledge and experience include the use of antimetabolite therapy. Because of the possibility of serious toxic reactions (which can be fatal), Otrexup should be used only in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician’s care throughout therapy [see Warnings and Precautions ( 5.1 )]. 1. Methotrexate can cause embryo-fetal toxicity, including fetal...
What it is approved for
From the label in effect Jan 31, 2025.
Otrexup is a folate analog metabolic inhibitor indicated for the: • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy ( 1.1 ). • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy ( 1.2 ). Limitation of Use Otrexup is not indicated for the treatment of neoplastic diseases ( 1.3 ). 1.1 Rheumatoid Arthritis including Polyarticular Juvenile Idiopathic Arthritis Otrexup is indicated in the management of selected adults with severe, active rheumatoid arthritis (RA) (ACR criteria), or children with active polyarticular juvenile idiopathic arthritis (pJIA), who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs). 1.2 Psoriasis Otrexup is indicated in adults for the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation. It is important to ensure that a psoriasis “flare” is not due to an undiagnosed concomitant disease affecting immune responses. 1.3 Limitation of Use Otrexup is not indicated for the treatment of neoplastic diseases.
Mechanism: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. The mechanism of action in rheumatoid arthritis is unknown; it may...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 11, 2013 Original approval · Efficacy ReviewLabelLetter
- Oct 11, 2013 Original approval · Type 5 - New Formulation or New Manufacturer ReviewLabelLetter
14 products under this application
- OTREXUP · METHOTREXATE 22.5MG/0.4ML (22.5MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP PFS · METHOTREXATE 25MG/ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 12.5MG/0.4ML (12.5MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP PFS · METHOTREXATE 20MG/0.8ML (20MG/0.8ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 25MG/0.4ML (25MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP PFS · METHOTREXATE 15MG/0.6ML (15MG/0.6ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 15MG/0.4ML (15MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP PFS · METHOTREXATE 10MG/0.4ML (10MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 17.5MG/0.4ML (17.5MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP PFS · METHOTREXATE 22.5MG/0.9ML (22.5MG/0.9ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 7.5MG/0.4ML (7.5MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP PFS · METHOTREXATE 17.5MG/0.7ML (17.5MG/0.7ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 20MG/0.4ML (20MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
- OTREXUP · METHOTREXATE 10MG/0.4ML (10MG/0.4ML) · SOLUTION, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.
- Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic LymphomaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01190930 · 9,350 participants · Start Aug 11, 2010 · Primary completion Mar 31, 2019
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Adult B Lymphoblastic Lymphoma; Ann Arbor Stage I B Lymphoblastic Lymphoma and 7 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 243 sites in all
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
University Hospital Schleswig-HolsteinAcademic, hospital or other
NCT01117441 · 6,136 participants · Start Jun 2010 · Primary completion Dec 31, 2021
Drug: PEG-L-asparaginase; cyclophosphamide and 14 more · For: Leukemia
Sites: Randwick, Australia; Westmead, Australia; Dornbirn, Austria · 139 sites in all
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive MutationsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT02883049 · 5,949 participants · Start Feb 29, 2012 · Primary completion Dec 31, 2022
Drug: Clofarabine; Cyclophosphamide and 14 more · For: B Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, BCR-ABL1-Like; Central Nervous System Leukemia and 1 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 239 sites in all
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT00103285 · 5,377 participants · Start Apr 11, 2005 · Primary completion Dec 30, 2013
Drug: Cyclophosphamide; Cytarabine and 8 more · For: Acute Lymphoblastic Leukemia; Childhood B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 236 sites in all
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Pivotal-lookingRecruiting
Martin SchrappeAcademic, hospital or other
NCT03643276 · 5,000 participants (planned) · Start Jul 15, 2018 · Primary completion Jul 14, 2028
Drug: Blinatumomab; Bortezomib and 17 more · For: Acute Lymphoblastic Leukemia, Pediatric
Sites: Sydney, Australia; Westmead, Australia; Graz, Austria · 115 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective75,997
- rheumatoid arthritis38,640
- arthralgia36,856
- pain36,004
- off label use35,326
- fatigue29,671
- nausea24,467
- joint swelling22,658
- headache21,327
- rash20,369
- condition aggravated20,265
- drug intolerance20,024
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 5,129 |
| 2005 | 5,083 |
| 2006 | 4,969 |
| 2007 | 7,782 |
| 2008 | 8,995 |
| 2009 | 9,160 |
| 2010 | 9,678 |
| 2011 | 10,610 |
| 2012 | 14,953 |
| 2013 | 16,975 |
| 2014 | 16,967 |
| 2015 | 20,365 |
| 2016 | 21,909 |
| 2017 | 22,749 |
| 2018 | 32,398 |
| 2019 | 32,440 |
| 2020 | 39,843 |
| 2021 | 26,547 |
| 2022 | 29,258 |
| 2023 | 26,872 |
| 2024 | 23,124 |
| 2025 | 20,104 |
| 2026 | 11,726 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Otrexup (Methotrexate/PF)
2024 spending
$7.5M
Beneficiaries
1,385
7,988 claims
Per beneficiary
$5,446
$452.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,612,125 |
| 2021 | $7,533,587 |
| 2022 | $7,438,959 |
| 2023 | $8,088,436 |
| 2024 | $7,542,059 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- First-Line Treatment of Pulmonary Sarcoidosis with Prednisone or Methotrexate.
Kahlmann V, Janssen Bonás M, Moor CC, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Equivalence Trial
- Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: A systematic review and network meta-analysis of randomized clinical trials.
Spencer RK, Jin JQ, Elhage KG, et al. · J Am Acad Dermatol 2023 · Letter, Network Meta-Analysis
- Medical treatment of uterine arteriovenous malformation: a systematic review and meta-analysis.
Rosen A, Chan WV, Matelski J, et al. · Fertil Steril 2021 · Comparative Study, Meta-Analysis
- Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
Ridker PM, Everett BM, Pradhan A, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.
Liu T, Wang L, Zhang X, et al. · JAMA Netw Open 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group.
Mazewski C, Leary SES, Kang G, et al. · Neuro Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Cosette · Also marketed as Otrexup Pfs
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.